CRVS
NASDAQ · Biotechnology
Corvus Pharmaceuticals Inc
$12.56
+0.01 (+0.08%)
Open$12.53
Previous Close$12.55
Day High$12.61
Day Low$12.25
52W High$26.95
52W Low$5.72
Volume—
Avg Volume1.10M
Market Cap1.03B
P/E Ratio—
EPS$-0.62
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+261.5% upside
Current
$12.56
$12.56
Target
$45.40
$45.40
$29.32
$45.40 avg
$54.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Net Income | 40.80M | 37.35M | 36.12M |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |
| Rev Growth | +19.0% | -0.6% | +17.7% |
| Debt/Equity | 0.54 | 0.42 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.55 | +0.40% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $409.22 | +4.08% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $519.07 | +1.63% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $811.01 | +1.61% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $253.98 | +3.95% | 40.0 | 32.33B |